Ocugen, Inc. Announces U.S. FDA Lifts Clinical Hold on the Submission of Its Investigational New Drug Application for Its COVID-19 Vaccine Candidate COVAXIN™ (BBV152)
MALVERN, Pa., Feb. 18, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical…
Advancing Brain–Computer Interfaces for Rehabilitation and Assistive Technologies
HeyNews Launches AdApt to Rewrite Sponsor Ad Copy in Newsletter Publishers’ Own Voice